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Abstract
A hexanucleotide repeat expansion in C9ORF72 has been established as a common cause of frontotemporal dementia (FTD).
However, the minimum repeat number necessary for disease pathogenesis is not known. The aims of our study were to
determine the frequency of the C9ORF72 repeat expansion in two FTD patient collections (one Australian and one Spanish,
combined n = 190), to examine C9ORF72 expansion allele length in a subset of FTD patients, and to examine C9ORF72 allele
length in ‘non-expansion’ patients (those with ,30 repeats). The C9ORF72 repeat expansion was detected in 5–17% of
patients (21–41% of familial FTD patients). For one family, the expansion was present in the proband but absent in the
mother, who was diagnosed with dementia at age 68. No association was found between C9ORF72 non-expanded allele
length and age of onset and in the Spanish sample mean allele length was shorter in cases than in controls. Southern
blotting analysis revealed that one of the nine ‘expansion-positive’ patients examined, who had neuropathologically
confirmed frontotemporal lobar degeneration with TDP-43 pathology, harboured an ‘intermediate’ allele with a mean size
of only ,65 repeats. Our study indicates that the C9ORF72 repeat expansion accounts for a significant proportion of
Australian and Spanish FTD cases. However, C9ORF72 allele length does not influence the age at onset of ‘non-expansion’
FTD patients in the series examined. Expansion of the C9ORF72 allele to as little as ,65 repeats may be sufficient to cause
disease.
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Introduction
Frontotemporal dementia (FTD) is a clinically diagnosed
syndrome including a wide spectrum of features, usually leading
to a progressive dementia and often accompanied by motor
features including parkinsonian syndromes or amyotrophic lateral
sclerosis (ALS). FTD can present clinically with personality and
behavioural changes (termed behavioural variant FTD, bvFTD) or
language deficits (including syndromes termed semantic dementia
(SMD) and progressive non-fluent aphasia (PNFA)) [1]. FTD can
also present with memory deficits similar to those observed in
Alzheimer’s disease (AD), which can complicate diagnosis.
Corticobasal syndrome (CBS) and progressive supranuclear palsy
syndrome (PSPS) are related clinical diagnoses that show
substantial pathological overlap with FTD [2].
The underlying pathology of FTD (termed frontotemporal lobar
degeneration, FTLD) includes atrophy often most prominent in
the frontal and temporal regions, together with the presence of
degenerating neurons with intracellular inclusions that are
immunopositive for either microtubule-associated protein tau
(classed as FTLD-tau) or ubiquitin (FTLD-U). The ubiquitin-
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positive inclusions are also positive for either TAR DNA binding
protein 43 (FTLD-TDP) or fused in sarcoma protein (FTLD-FUS)
[2].
Mutations in the genes encoding tau (MAPT) and progranulin
(GRN) have both been shown to lead to FTD, with CHMP2B and
VCP mutations leading to FTD in rarer cases [3]. Recently, a
hexanucleotide repeat expansion in chromosome 9 open reading frame
72 (C9ORF72), a gene of unknown function on chromosome 9p21,
was reported as a major cause of disease in Finnish and North
American FTD and ALS cohorts [4,5], and has been observed in
FTD and ALS cohorts worldwide [6]. An increased prevalence of
psychosis has been observed [7,8] and parkinsonism has been
reported as a common phenotype [9,10] in C9ORF72-positive
FTD patients. Single nucleotide polymorphism (SNP) analysis has
indicated that most expansion carriers share a common haplotype
covering the C9ORF72 gene and surrounding region, which is
tagged by the A allele of SNP rs3849942, and indicates that these
individuals are descended from a common ancestor [6,11–13].
Two previous studies have indicated that there is no increased
risk of ALS [13] or FTD [8] associated with C9ORF72 allele
lengths below that currently defined as an ‘expansion’ ($30
repeats). However, it is not yet established whether this is true for
all populations. In addition, current polymerase chain reaction
(PCR)-based assays cannot distinguish between those subjects with
,50 repeats and those with larger numbers of repeats: thus it is
not yet known what the minimum number of repeats is to cause
disease. We therefore examined the frequency of this repeat
expansion in a collection of Australian and Spanish FTD patients
and compared allele length in non-expansion FTD patients and
healthy controls in different populations. We also analysed
genomic DNA by Southern blotting to determine the approximate
number of repeats in selected expansion carriers. We determined
that C9ORF72 expansion was a frequent cause of disease in our
patients, and that repeat numbers as little as ,65 repeats may be
sufficient to cause disease. However, repeats ,30 units were not
associated with risk of disease or age of onset in non-expansion
FTD patients.
Results
We examined the C9ORF72 gene in a collection of Australian
and Spanish FTD patients (Table 1). We identified C9ORF72
repeat expansions in 23 of the 190 unrelated patients screened in
the two FTD groups (12.1%). The expansion was found in 19.8%
(18/91) of the Australian patients and 5.1% (5/99) of the Spanish
patients. In the subgroup of patients with a positive family history
of early-onset (,65 y) dementia or ALS, the frequency rose to
40.5% (15/37) and 21.4% (3/14), respectively.
We reviewed available clinical notes of expansion-positive
patients (Table 2). For those expansion carriers where the subtype
of FTD was specified (n = 10), the most common diagnosis was
bvFTD (n = 7, 70.0%) (Table 2). Two patients were diagnosed
with combined FTD and ALS (FTD-ALS). One Spanish patient
was diagnosed with PNFA. In the Spanish patient collection, the
expansion was present in 4/73 (5.5%) of all bvFTD patients, and
3/10 (30%) of those bvFTD patients with a positive family history.
The majority of expansion-positive patients had a positive family
history of early-onset dementia or ALS (14/17, 82.4%). Of the
three family history-negative patients, one reported early death of
a parent, one reported a mother with anecdotal multiple sclerosis
but no further clinical information available on this diagnosis, and
one lacked sufficient family history information.
We examined the frequency of psychosis, ALS and parkinson-
ism, phenotypes commonly associated with FTD, in C9ORF72
expansion carriers (Table 2). Psychosis was reported either in the
proband or in an affected family member in 6/13 (46.2%)
expansion-positive patients (4/9 Australian cases and 2/4 Spanish
cases). ALS was reported either in the proband or in an affected
family member in 8/12 (66.7%) Australian expansion-positive
cases. Only five patients in the Spanish series had a personal or
family history of ALS and none harboured the C9ORF72
mutation. No C9ORF72 expansion-positive FTD patients reviewed
here reported a personal or family history of parkinsonism,
although 1/6 C9ORF72 carriers from this group that were
reported previously [8] exhibited parkinsonian features.
Segregation of repeat expansion
DNA was available from affected family members for four
expansion-positive probands (cases 4 & 12 reported here and cases
97 & 105 reported previously [8]). For three families, segregation
analysis showed that the expansion was present in all available
affected members and absent in all available unaffected members.
One of these families was previously reported to contain a
mutation in the SIGMAR1 gene (c.672*51G.T, family Aus-14)
[14,15]. We subsequently screened the other Australian SIGMAR1
case (from family Aus-47, with SIGMAR1 substitution
c.672*26C.T) [15] and did not detect a C9ORF72 expansion in
this patient. For the fourth family, the mutation was present in the
proband (diagnosed with bvFTD, onset age 56) but not his
mother, who had developed dementia at age 68. When seen at age
78, the mother had clinical features much more suggestive of AD
than FTD. In particular, in contrast to her son, she was not
disinhibited or inappropriate, and had marked impairment in
memory, language and orientation. The proband’s father was said
to have shown unusual behaviours and to have had several siblings
with ALS and a parent with Parkinson’s disease; these could not be
confirmed at the time but in retrospect they were probably
important.
Table 1. Demographic information of FTD patient groups.
Group No. cases (M/F) Age at onset (y) (mean±SD) Clinical diagnosis Family history (%)
Australian 91 (53/38) 58.7611.8 8 bvFTD, 6 CBS, 9 FTD-ALS, 9 FTDP,
50 FTDuns, 5 PNFA, 2 SMD, 2 atypical AD
40.7
Spanish 99 (51/47)* 67.1610.2 69 bvFTD, 6 FTDm, 4 FTD-ALS, 5 FTDP,
10 PNFA, 5 SMD
14.1
bvFTD = behavioural variant FTD; CBS = corticobasal syndrome; D = death; F = female; FTD-ALS = FTD with amyotrophic lateral sclerosis; FTDP = FTD with parkinsonism;
FTDm = FTD with mixed phenotype; FTDuns = FTD otherwise unspecified; M = male; PNFA = progressive non-fluent aphasia; SMD = semantic dementia.
*Gender information not available for one patient.
doi:10.1371/journal.pone.0056899.t001
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We examined C9ORF72 allele length in expansion-negative
FTD patients (73 Australian, 94 Spanish) and healthy controls
(275 Australian [8], 186 Spanish) to determine whether non-
expansion alleles were associated with FTD phenotypes. We first
examined whether demographic variables were correlated with the
estimated expansion size. Using linear regression, gender was not
significantly correlated with either mean or maximum repeat
length in the Australian or Spanish cohort. Age was similarly not
correlated with either mean or maximum repeat length in both
cohorts. Mean and longest allele length were not associated with
presence of disease in the Australian series (mean number of
repeats 6 SEM: cases 4.560.3, controls 4.460.1; longest repeat
number: cases 6.060.4, controls 6.060.2; both p.0.05). However
mean repeat length was significantly shorter in Spanish cases
relative to controls (cases 4.160.2, controls 4.860.2, df = 224.5,
p= 0.005). Maximum allele length was also significantly shorter in
Spanish cases relative to controls (cases 5.560.3, controls 6.760.3,
df = 221.0, p= 0.007). Mean allele length was not a significant
predictor of age of onset in a linear regression analysis in either
FTD group (Australian: b= 0.093, t= 0.780, p= 0.438; Spanish:
b=20.083, t=20.785, p= 0.435). We repeated these analyses
using longest allele length as a predictor, and again no significant
associations were found.
Expansion allele size estimation
We estimated the number of repeats in expansion alleles from
nine Australian patients with sufficient DNA to perform Southern
blotting: cases 1 & 4 reported here, plus three affected relatives of
case 4 (IDs III-7, IV-1 & III-2 in family Aus-14 [14,15]) and cases
90, 100, 101 & 103 from the neuropathologically ascertained
cohort reported previously [8]. Eight patients harboured expan-
sion alleles in the 1000–1600 repeats range (Figure 1A, Figure S1),
within the range of expansion allele sizes reported previously [4].
In contrast, case 100 showed an estimated allele size ranging from
50–80 repeats (mean allele size ,65 repeats). This man gave up
driving at 53 because he was confused about which pedals to use.
He stopped work at 58 and became socially withdrawn and
egocentric, also developing delusions that the television was
attached to his head or that fluid was running out of his legs. He
developed incontinence and was admitted to residential care at age
66 years. He was treated with pericyazine and developed
parkinsonian features, becoming increasingly impaired until his
death at age 76. There was no report of symptoms consistent with
ALS. Analysis of his brain post mortem led to a neuropathological
diagnosis of frontotemporal lobar degeneration with type B TDP-
43 pathology [8]. There was no family history of diagnosed
dementia, although his mother was said to be vague when she died
in a nursing home in her eighties. A half-sister had been treated
with several courses of electro-convulsive therapy for a nervous
Table 2. Disease characteristics of 17 C9ORF72 mutation carriers.
Group Patient Sex Age at onset (y) Clinical diagnosis FH notes FH score Psychosis* ALS*
Australia 1 M 52 Probable FTD Twin ALS d41 3 No (Yes)
Australia 2 M 43 bvFTD Mother dementia d52 2 Yes No
Australia 3 M ,57 bvFTD Mother AD d67, aunt AD
d74, uncle FTLD-U
2 N/A (Yes)
Australia 4 M 59 bvFTD 10 relatives FTD
and/or ALS
2 (Yes) (Yes)
Australia 5 F 52 FTD-ALS Sister, mother, uncle,
grandmother dementia
1 N/A (Yes)
Australia 6 M 65 FTD-ALS 8 relatives dementia or
ALS
2 No Yes
Australia 7 M 41 AD with R sided neglect No FH (mother d,40) 4 N/A No
Australia 8 M 55 FTD Mother dementia d65 3 No No
Australia 9 F 62 FTD Brother ALS, mother
dementia+scz
2 (Yes) (Yes)
Australia 10 F ,64 FTD Mother dementia d70 3 No No




Australia 12 F 41 FTD Brother dementia,
mother ALS d 42
2 (Yes) (Yes)
Spain 13 F 56 bvFTD Brother DLB 3 N/A No
Spain 14 M 64 bvFTD - 4 No No
Spain 15 F 63 bvFTD Mother dementia 3 No No
Spain 16 F 70 PNFA (Mother multiple sclerosis) 4 Yes No
Spain 17 M 51 bvFTD Brother, father dementia 2 Yes No
Data presented only for those C9ORF72-positive cases not previously reported. Details of six additional C9ORF72-positive cases have been reported previously [8].
AD = Alzheimer’s disease, bvFTD = behavioural variant FTD, d41 = died at age 41, DLB = dementia with Lewy bodies, F = female, FH = family history, FTD-ALS = FTD with
amyotrophic lateral sclerosis, M = male, PBP = pseudobulbar palsy, scz = schizophrenia; SMD = semantic dementia, N/A = data not available.
*Data for family members is in parentheses.
doi:10.1371/journal.pone.0056899.t002
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breakdown. Genotyping of case 100 revealed that he was
homozygous for allele A of rs3849942, the allele used as a
surrogate marker for the chromosome 9p21 risk haplotype
previously associated with FTD and ALS [11].
We examined demographic variables with respect to estimated
expansion size. Mean estimated expansion size did not signifi-
cantly differ between males and females (mean allele sizes 6 SEM
12136297 versus 1300661, p.0.05). Linear regression analysis
revealed no significant association between repeat number and age
of onset (adjusted R2 =20.142, b= 0.027, t= 0.073, p.0.05)
(Figure 1B). This analysis was repeated with the case with the low
repeat number excluded, but this did not affect the results.
Discussion
We have screened two clinically ascertained patient collections
for the hexanucleotide repeat expansion in C9ORF72 that has
recently been implicated in FTD and ALS [4,5]. We identified
expansions in 21 FTD probands, and determined the frequency of
C9ORF72 expansions to be 21–41% in familial FTD cases.
Psychosis was a frequent observation in C9ORF72 mutation
carriers (46%), and, in the Australian series, the repeat expansion
was common in FTD families with ALS features. We did not find
any evidence for an increased prevalence of parkinsonism in
C9ORF72 mutation carriers, in agreement with some [16,17], but
not all previous reports [9,10]. C9ORF72 expansion patients were
mostly of the bvFTD subtype: one carrier was identified with
PNFA, which has been observed previously [5,7,9,18].
The frequency of C9ORF72 expansion in the Spanish familial
FTD patient group is in line with recent estimates in European
ancestry cohorts (2–19%) [6]. The relatively high frequency of
C9ORF72 mutations in the Australian patients is likely due to
ascertainment bias, as this series was recruited by clinicians with
an interest in early-onset dementia submitting blood for DNA
analysis, where a clinical suspicion might be high for genetic
mutation. In contrast, the Spanish subjects were recruited
independently of positive FTD/ALS family history.
The exact size for the expanded allele in the C9ORF72 is
difficult to estimate by any other means than Southern blotting
given our existing technology. As with other large expanded
repeats, such as those for involved in myotonic dystrophies [19],
Southern blotting typically reveal a smear corresponding to
somatic instability within the cell population containing a range
in size of the expanded allele (Figure 1, Figure S1). The presence
of faint 3.9 kb band may have arisen as a result of the probe
binding to homologous sequences, or subtle differences in DNA
quality. The band was observed in all cases, with the exception of
one affected member from the Aus-14 FTD-ALS family
Of interest is the finding that the Aus-14 FTD-ALS family that
carries a mutation in SIGMAR1 [15] also contains the C9ORF72
repeat expansion (Case 4 in Table 2). The one family member
presenting as a putative phenocopy, i.e. lacking the SIGMAR1
variant, carries the C9ORF72 repeat expansion. Thus, the most
parsimonious explanation is that the C9ORF72 expansion, and not
the SIGMAR1 mutation, is causative of disease in this family.
However, the unrelated Australian SIGMAR1 case reported in
Luty et al [15] does not carry the C9ORF72 repeat expansion. The
identification by genome-wide homozygosity mapping of a
SIGMAR1 missense mutation in a family with autosomal recessive
ALS [20] indicates that SIGMAR1 may still play a role in the
pathogenesis of ALS and FTD. In addition, recent studies
reporting ALS patients with mutations in established causative
genes (e.g., SOD1, TARDBP) in addition to C9ORF72 [21–24]
suggest that more than one pathogenic mutation may be required
to cause disease in some ALS cases.
The C9ORF72 repeat expansion largely segregated with disease
in pedigrees where affected family members were available for
testing, with one exception. We identified one family where the
proband’s late-onset affected mother (onset at age 68) was negative
for the expansion. As we had access only to lymphocyte DNA from
the mother we cannot rule out somatic mosaicism as a possible
explanation for the negative finding, but given the paternal family
history it seems more likely that she was a phenocopy. It should be
noted the affected mother was homozygous for the ‘G’ allele of
rs3849942 (data not shown), which is not associated with the
common expansion haplotype [4,5]. This lends further support
that the mutant repeat expansion may not have been transmitted
Figure 1. Analysis of C9ORF72 expansion allele size. A, Southern
blot analysis of five unrelated probands and four Aus-14 family
members with the C9ORF72 repeat expansion, plus an expansion-
negative control (N). Wild-type (wt) and expansion (exp) alleles are
indicated; the smaller expansion allele in case 100 is arrowed. A band
running at ,3.8 kb was also observed (asterisk); this probably arises
from unspecific probe binding. B, Scatter plot of age of onset of disease
versus estimated mean number of C9ORF72 hexanucleotide repeats in
expansion allele carriers.
doi:10.1371/journal.pone.0056899.g001
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through her. Although the family history on the father’s side was
unconfirmed, in retrospect it was relevant. The identification of
this probable phenocopy highlights the need to maintain a high
index of suspicion when considering family histories, as the most
obvious conclusion may be misleading.
We did not detect an association between C9ORF72 allele
length on FTD diagnosis or age of onset in the Australian patient
group, implying that there is little pathogenic effect of a C9ORF72
allele with fewer than 30 repeats. This is consistent with previous
studies on FTD, ALS and FTD-ALS cohorts [8,13,25]. In our
Spanish series, we detected a statistically significant increase in
both mean and maximum allele length in controls relative to cases.
However, it is premature to speculate on its significance until the
biological mechanism behind the pathogenicity of C9ORF72 allele
length has been elucidated, and our findings replicated in
independent cohorts of similar ethnic ancestry and disease status.
We did not detect a significant effect of expansion allele size on
age of onset. However, the difficulty of accurate allele sizing with
Southern blot analysis, most probably due to somatic mosaicism,
and the small sample numbers available to us in this study mean
that it is premature to draw conclusions from these findings. This
analysis, however, did identify one patient with a C9ORF72 allele
comprising ,65 repeats. To our knowledge, this is the smallest
C9ORF72 ‘expansion’ allele thus far reported in an FTD patient.
This patient did not exhibit a late onset of disease, as might have
been expected for someone harbouring a relatively small
expansion. Studies have determined that most if not all
C9ORF72 expansion carriers share the same haplotype, implying
that they are descended from a common ancestor [6,11–13].
Recent discussion has centred on whether the C9ORF72 expansion
occurred only once on this haplotype and that this expansion has
been inherited by all C9ORF72-positive patients, or if the
haplotype represents an unstable C9ORF72 allele that is prone to
expansion, and has expanded to pathogenic lengths multiple times
independently [12]. The detection of a C9ORF72 allele with ,65
repeats in an individual with the presumptive ‘risk’ haplotype is
consistent with the ‘multiple expansion’ hypothesis.
In the absence of affected relatives to check for segregation with
disease, it is not possible to determine conclusively whether the
expansion to ,65 repeats is causative of disease in this patient or
merely a coincidental finding. However, in support of the former
possibility, we note that this patient was given a neuropathological
diagnosis of FTLD-TDP type B, the same pathology observed for
the majority of C9ORF72 expansion-positive cases [7–9,26]. If
truly pathogenic, this allele size may represent close to the
minimum number of repeats necessary to cause disease. The
minimum C9ORF72 repeat number that invariably leads to FTD
remains to be determined, as we and others have found a small
number of apparently healthy controls with .30 repeats [8,9,23],
and another study has reported reduced penetrance in some
C9ORF72 expansion-positive families [27]. Future large-scale
Southern blot analyses of expansion-positive patients are required
to establish exactly where the threshold for disease lies, as this
information will have implications for genetic counselling for the
substantial proportion of FTD patients who have been determined
to be C9ORF72 expansion positive by repeat-primed PCR.
Materials and Methods
Ethics statement
The procedures in this study were approved by the University of
New South Wales and South Eastern Sydney Local Health District
(Northern Region) Human Research Ethics Committees and the
University of Navarra School of Medicine Ethics Committee.
Written informed consent was collected from each participant or
his/her guardian for brain donation and/or DNA collection.
Subjects
We screened two patient groups: 91 patients from Australia and
99 from Spain (Table 1). All patients with MAPT or GRN
mutations were previously excluded by standard DNA sequencing
of the entire coding gene region.
The Australian patient group consists of patients recruited or
referred for DNA studies of non-Alzheimer dementia since 1994,
via specialist dementia clinics, neurologists, psychiatrists, geriatri-
cians or genetic clinics. Patients were included if they had clinical
features of FTD, dementia with frontal features, dementia
otherwise atypical for AD, frontal neurodegenerative syndromes
such as CBS or PSPS, and/or a family history of dementia or ALS.
Of these 91 cases, 10 subsequently came to autopsy and formed
part of the neuropathologically ascertained cohorts whose
C9ORF72 screening was reported previously [8]. Six of these 10
cases were positive for the C9ORF72 expansion. The Spanish
patient group was recruited at the Departments of Neurology of
the following centres in Spain: Clı´nica Universidad de Navarra
(Pamplona), Hospital do Salne´s (Pontevedra) and Hospital de
Bellvitge (Barcelona). It included independent FTD subjects
diagnosed with sporadic or familial FTD.
Familial FTD was considered when the proband had a first-
degree relative clinically diagnosed with dementia. Presence or
absence of psychosis was evaluated by report from the referring
clinician, based on neurologist and/or next-of-kin observations.
Family history was scored according to a modified version of the
Goldman scale [28], as detailed in Table S1.
We also screened 186 healthy Spanish controls with an average
age of 64.2 years (range 19–87 years) at collection [29]. Australian
patient allele sizes were compared with those from a cohort of 275
healthy Australian controls with an average age of 78.5 years
(range 70–89 years), which was screened in a previous study [8].
Mutation screening
Genomic DNA was screened for the hexanucleotide repeat
expansion in C9ORF72 by repeat-primed PCR, and non-
expansion C9ORF72 allele sizes were determined as described
previously [8]. Southern blotting was performed on those patients
where peripheral blood lymphocyte genomic DNA was available
in sufficient quantities. DNA (10 mg) was digested with HindIII and
XbaI and separated on a 0.9% agarose gel. Fragments were
transferred by alkali blotting onto Amersham Hybond NTM-XL
(GE Healthcare) and hybridized to a 32P-labelled probe at 70uC
overnight. The filters were washed with Church’s wash buffer
(0.5 M sodium phosphate, 1% sodium dodecyl sulphate). Autora-
diography was for 4–6 days at 280uC. BstEII digested lambda
DNA was used as a size marker. Mean repeat number was used in
statistical analyses.
Statistical analysis
Statistical analyses were performed in IBM SPSS version 20.
Non-expansion allele length was compared between cases and
controls and expansion allele length was compared between males
and females by means of Student’s t test. We tested for
homogeneity of variance by using the Levene statistic. When the
Levene statistic was significant (p,0.05), the corresponding
contrast estimate based on unequal variances was used. The effect
of expansion and non-expansion allele length on age of onset was
assessed by linear regression analyses. P-values,0.05 were
considered to be statistically significant.
C9ORF72 in Australian and Spanish FTD Patients
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Supporting Information
Figure S1 Southern blot analysis of five unrelated
probands and three Aus-14 family members with the
C9ORF72 repeat expansion, plus an expansion-positive
control (+). Wild-type (wt) and expansion (exp) alleles are
indicated. The smaller expansion 2.9 kb allele in case 100 is
arrowed. A band running at ,3.8 kb was also observed (asterisk),
probably arising from unspecific probe binding.
(TIF)
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